TEST CATALOG ORDERING & RESULTS SPECIMEN HANDLING CUSTOMER SERVICE EDUCATION & INSIGHTS
Test Catalog

Test ID: ADIC    
Disseminated Intravascular Coagulation/Intravascular Coagulation and Fibrinolysis (DIC/ICF) Profile, Plasma

Method Description Describes how the test is performed and provides a method-specific reference

PTSC: Optical clot-based

Tissue thromboplastin (phospholipid and recombinantly-derived human tissue factor) and calcium are added to citrated plasma, bypassing the action of platelets and factors VIII, IX, XI, and XII in the intrinsic procoagulant pathway. The tissue thromboplastin-factor VII/VIIa complex activates factor X. Activated factor X (factor Xa) forms a complex with factor Va, calcium, and phospholipid to activate factor II (prothrombin) to thrombin. Thrombin then acts on fibrinogen (factor I) to form fibrin which clots, providing the assay endpoint (the "prothrombin time").(Package insert: HemosIL RecombiPlasTin 2G Instrumentation Laboratory Company, Lexington, MA, R0, 9/2007)

 

APTSC: Optical clot-based

The activated partial thromboplastin time (APTT) assay is performed on the Beckman Coulter ACL TOP. Patient plasma is combined and incubated with an APTT reagent containing phospholipid, a negatively charged contact factor activator, and buffer. After a specified incubation time, calcium is added to trigger the coagulation process in the mixture. Subsequently, the time to clot formation is measured optically using a wavelength of 671 nm. Mixing studies (see APTTM / APTT Mix 1:1) using normal pooled plasma are performed in the Special Coagulation Laboratory on samples with a prolonged APTT, to assist in discriminating between factor deficiency states and coagulation inhibitors, unless further testing is not indicated.(Poller L: Activated partial thromboplastin time (APTT). In Laboratory Techniques in Thrombosis; A Manual. Edited by J Jesperson, RM Bertina, F Haverkate. Dordrecht and London, Kluwer Academic Publishers, 1999, pp 337-343)

 

TTSC: Optical clot-based

The thrombin time (TT) assay is performed on the Instrumentation Laboratory ACL TOP. Patient plasma is combined with a bovine thrombin reagent containing bovine albumin, calcium chloride, and buffer immediately triggering the coagulation process in the mixture. Time to clot formation is measured optically using a wavelength of 405 nm.(Package insert: HemosIL Thrombin Time, Instrumentation Laboratory Company, Bedford, MA. Revision 10/2011)

 

CLFIB: Clauss assay

The Clauss fibrinogen assay is performed using the HemosIL Fibrinogen-C kit on the Instrumentation Laboratory ACL TOP. Patient plasma, containing fibrinogen, is mixed with reagent containing excess thrombin. The excess thrombin converts the fibrinogen in the patient plasma to fibrin. The amount of time it takes to form a clot is inversely proportional to the amount of fibrinogen present in the patient plasma.(Clauss A: Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957;17:237-246; Rossi E, Mondonico P, Lombardi A, Preda L: Method for the determination of functional [clottable] fibrinogen by the new family of ACL coagulometers. Thromb Res 1988;52:453-468; Hollensead SC, Triplett DA: Review of fibrinogen methods: clinical considerations. ASCP Check Specimen: 10[4] 1988 [TH 88-4]; Palareti G, Maccaferri M, Manotti C, et al: Fibrinogen assays: a collaborative study of six different methods. Clin Chem 1991;37:714-719)

 

DIMER: Latex immunoassay (LIA)

D-dimer is assayed in plasma by adding polystyrene latex particles coated with monoclonal antibodies specific for D-dimer domain. The latex particles agglutinate in the presence of soluble fibrin degradation products (FDP) containing the D-dimer domain. The degree of agglutination is directly proportional to the concentration of D-dimer in the sample and is determined by measuring the decrease of transmitted light caused by the aggregates (turbidimetric immunoassay).(Package insert: HemosIL D-Dimer HS 500. Instrumentation Laboratory Company, Bedford, MA 2/2017

PDF Report Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.

Monday through Friday; Varies

Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.

1-3 days

Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Clinic Laboratories until the release of the test result

7 days

Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

See individual test IDs

Performing Laboratory Location Indicates the location of the laboratory that performs the test

Rochester